NOTE 13  BUSINESS COMBINATIONS On April 10, 2015, we acquired 100% of the equity interests in Reeves-Sain Drug Store, Inc., a provider of retail and specialty pharmaceutical services. The acquisition expanded our presence in the specialty pharmacy arena  the largest growth area of the pharmacy industry. The total consideration for the purchase was approximately $66.0 million, less working capital adjustments of $10.3 million, which yielded an adjusted purchase consideration of $55.8 million. The Company incurred $0.5 million of transaction costs in connection with the acquisition. The transaction costs were expensed as incurred and are reflected in selling, general and administrative expenses in the consolidated statement of operations. The adjusted consideration consisted of $42.8 million in cash at the time of closing and $13.0 million in notes payable in three equal installments on January 31 st of 2021, 2022 and 2023. The notes payable have an adjustment mechanism based upon an earn-out provision that could result in an increase to the face value of the notes if certain financial metrics are achieved. No amounts have been reflected in the 2015 or 2016 consolidated financial statements for this provision. If and when the provision is met, the expense will be treated as compensation expense in that year. A summary of the purchase price allocation for Reeves-Sain Drug Store, Inc. is as follows (dollars in thousands): Total purchase consideration: Cash $ 42,757 Notes payable $ 13,000 Total purchase consideration $ 55,757 Allocation of the purchase consideration: Accounts receivables $ 14,474 Inventory $ 2,005 Other assets $ 307 Goodwill $ 41,403 Identifiable intangible assets $ 20,236 Total assets acquired $ 78,425 Accounts payable $ 21,448 Other current liabilities $ 1,220 Total liabilities assumed $ 22,668 Net assets acquired $ 55,757 The following are the identifiable intangible assets acquired and their respective weighted average useful lives, as determined based on valuations (dollars in thousands): Amoun